Panacea Pharmaceuticals Inc.
This article was originally published in Start Up
Executive Summary
Panacea Pharmaceuticals is developing products to detect and treat CNS diseases and cancer.
You may also be interested in...
New Approaches for Neurodegenerative Disorders
Neurodegenerative disorders represent a tremendous unmet medical need. Millions of people are affected by such diseases as Alzheimer's, Huntington's Parkinson's, MS and ALS, not to mention those suffering the neurodegenerative effects of stroke and spinal cord injury. And because many of these diseases are age-related, the already staggering numbers of patients will increase during the next several years as increasing life expectancies and changing demographics increase the percentage of older Americans. The market for neuroscience therapies is currently the fastest growing segment in pharmaceuticals, and is projected to become the leading therapeutic area within five years. Small wonder that new companies are entering the fray, hoping to capture a share of this multi-billion dollar opportunity as well as to finally offer a cure to the victims of these diseases.
Understanding How To Develop BTK Inhibitors In MS Is Evolving
Having a reversible BTK inhibitor in the multiple sclerosis armamentarium could be the best way to favorably impact the treatment landscape.
Science Matters: Setting The Stage For Using Wearables In Oncology Drug Development
Digital biomarkers using data collected with wearable devices are making their way into clinical trials, largely in cardiovascular, respiratory and rare disease settings around physical activity metrics.